Abstract
Cognitive event-related potentials (ERPs) have been used as a marker of cognitive function in patients with psychiatric and neurological disorders. In particular, the P300 potential has been widely utilized to study dementia and aging, because the P300 ERP component is easily observed and reflects attention and memory processing. However, the relationship between parameters of the P300 potential and the severity or type of cognitive impairment in patients with Alzheimers disease (AD) remains controversial. Because specific and effective anti-dementia treatments have recently become available for AD, more useful information is needed about the clinical aspects of this disease, including methods of making an accurate and early diagnosis, differentiation from vascular dementia and other degenerative dementias, assessment of severity, assessment of disease progression, evaluation of the response to treatment, and prediction of the prognosis. This mini-review described new discoveries on recent clinical application of ERPs in AD with respect to the above-mentioned areas. Although the definition of normal ERP values and the most appropriate method of ERP recording in AD patients have not been well defined, recent findings suggest that ERP analysis may be a clinically useful, inexpensive, noninvasive, and reliable method of assessing AD.
Keywords: Cognitive event-related potentials, P300, Alzheimers disease
Current Alzheimer Research
Title: Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease
Volume: 1 Issue: 1
Author(s): Eiichi Katada, Koichi Sato, Kosei Ojika and Ryuzo Ueda
Affiliation:
Keywords: Cognitive event-related potentials, P300, Alzheimers disease
Abstract: Cognitive event-related potentials (ERPs) have been used as a marker of cognitive function in patients with psychiatric and neurological disorders. In particular, the P300 potential has been widely utilized to study dementia and aging, because the P300 ERP component is easily observed and reflects attention and memory processing. However, the relationship between parameters of the P300 potential and the severity or type of cognitive impairment in patients with Alzheimers disease (AD) remains controversial. Because specific and effective anti-dementia treatments have recently become available for AD, more useful information is needed about the clinical aspects of this disease, including methods of making an accurate and early diagnosis, differentiation from vascular dementia and other degenerative dementias, assessment of severity, assessment of disease progression, evaluation of the response to treatment, and prediction of the prognosis. This mini-review described new discoveries on recent clinical application of ERPs in AD with respect to the above-mentioned areas. Although the definition of normal ERP values and the most appropriate method of ERP recording in AD patients have not been well defined, recent findings suggest that ERP analysis may be a clinically useful, inexpensive, noninvasive, and reliable method of assessing AD.
Export Options
About this article
Cite this article as:
Katada Eiichi, Sato Koichi, Ojika Kosei and Ueda Ryuzo, Cognitive Event-Related Potentials: Useful Clinical Information in Alzheimers Disease, Current Alzheimer Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567205043480609
DOI https://dx.doi.org/10.2174/1567205043480609 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation and Function of DNA and Histone Methylations
Current Pharmaceutical Design Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Editorial (Thematic Issue: Mechanisms of Atherogenesis and Development of Anti-Atherosclerotic Therapy)
Current Pharmaceutical Design Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimer Research Preactive Multiple Sclerosis Lesions Offer Novel Clues for Neuroprotective Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets Metal Protein Attenuating Compounds (MPACs): An Emerging Approach for the Treatment of Neurodegenerative Disorders
Current Bioactive Compounds Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches
Current Pharmaceutical Design Aging in Down Syndrome and the Development of Alzheimer’s Disease Neuropathology
Current Alzheimer Research Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Current Alzheimer Research Cholinesterase Inhibitors Slow Decline in Executive Functions, Rather than Memory, in Alzheimers Disease: A 1-Year Observational Study in the Sunnybrook Dementia Cohort
Current Alzheimer Research Editorial (Hot Topic :Treatment with Antidepressants)
Current Pharmaceutical Design Implementation of Dynamic Lighting in a Nursing Home: Impact on Agitation but not on Rest-Activity Patterns
Current Alzheimer Research From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus
Current Diabetes Reviews Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes
Current Alzheimer Research Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis
CNS & Neurological Disorders - Drug Targets Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease
Current Alzheimer Research Beneficial Effects of the β-Secretase Inhibitor GRL-8234 in 5XFAD Alzheimer’s Transgenic Mice Lessen During Disease Progression
Current Alzheimer Research